R Squared’s Avidity Biosciences RNAM Stock Holding History

R Squared’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-490	Closed	-$14.2K	–	1239
2024 Q4	$14.2K	Buy	+490	New	+$20.5K	0.01%	1032

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

R Squared's RNAM Position: Q1 2025 in Review

R Squared sold out of Avidity Biosciences (RNAM) in Q1 2025, closing a stake of 490 shares — an estimated $14.2K sold.

R Squared first reported a position in RNAM in Q4 2024 and held it in 1 quarter. The position peaked at $14.2K in Q4 2024. 220 funds tracked by Wall St. Rank hold RNAM as of Q1 2025.

R Squared reported no remaining Avidity Biosciences position as of Q1 2025 after selling out during the quarter.
R Squared sold 490 Avidity Biosciences shares in Q1 2025, an estimated $14.2K.
R Squared first reported a position in Avidity Biosciences in Q4 2024 and held it in 1 quarter.
R Squared's Avidity Biosciences position peaked at $14.2K in Q4 2024.
220 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.